Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
Patients on QNEXA® Had Reduction in Cardiovascular Risk Factors Associated with Sustained Weight Loss Over Two Years
MOUNTAIN VIEW, Calif., March 31, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that data on QNEXA®, its investigational drug candidate, will be featured in a poster presentation at the 60th Annual Scientific Meeting of The American College of Cardiology, being held April 2-5, 2011 in New Orleans, Louisiana.
Following are details about the poster presentation:
The poster will be presented in Hall F of The Ernest N. Morial Convention Center in New Orleans, Louisiana on Sunday, April 3, 2011, 1:45 PM to 4:45 PM (Session 1048)
The Presenter, Dr. Michael H. Davidson, will be at the poster from 3:30 PM to 4:45 PM.
Presenter: |
Michael Davidson, MD, FACC, FACP, FNLA |
|
Authors: |
Davidson, Bowden, Day |
|
Title: |
Weight Loss and Cardiovascular Risk Reduction Over Two Years with Controlled-Release Phentermine-Topiramate (Presentation Number 1048-293) |
|
About QNEXA Controlled Release Capsules
QNEXA [kyoo-nek-suh] is an investigational drug candidate being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. QNEXA is a once-a-day, proprietary, oral, controlled-release formulation of low-dose phentermine and topiramate, which is designed to decrease appetite and increase satiety (the sense of feeling full), the two main mechanisms that impact eating behavior. In phase 2 and 3 clinical data to date, patients taking QNEXA have demonstrated statistically significant weight loss, glycemic control, and improvement in cardiovascular risk factors, when used in combination with a diet and lifestyle modification program.
About VIVUS
VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. QNEXA® is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com
CONTACT: |
|||
VIVUS, Inc. |
Investor Relations: |
The Trout Group |
|
Timothy E. Morris |
Brian Korb |
||
Chief Financial Officer |
646-378-2923 |
||
650-934-5200 |
|||
SOURCE VIVUS, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article